文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

Auxora对比安慰剂治疗重症COVID-19肺炎患者:一项随机对照临床试验

Auxora vs. placebo for the treatment of patients with severe COVID-19 pneumonia: a randomized-controlled clinical trial.
PubMed 文献 · Crit Care · 2022-04-08
一句话结论在重症COVID-19肺炎需鼻导管吸氧且推算PaO2/FiO2≤200的患者中,Auxora组第30天全因死亡率7.7% vs 安慰剂17.6%(P=0.0165),第60天死亡率及恢复时间无显著差异。

CARDEA是一项2期随机双盲安慰剂对照试验,评估在皮质类固醇和标准治疗基础上加用CRAC通道抑制剂Auxora治疗成人重症COVID-19肺炎。纳入需高流量或低流量鼻导管吸氧、基线推算PaO2/FiO2>75且≤300、未接受无创或有创机械通气的患者,主要终点为至第60天的恢复时间。因COVID-19住院率下降及监管指南禁止的标准治疗药物使用,试验提前终止。预设疗效集为基线推算PaO2/FiO2≤200的261例患者(Auxora组130例、安慰剂组131例),恢复时间7天 vs 10天(P=0.0979),第60天全因死亡率13.8% vs 20.6%(P=0.1449),第30天全因死亡率7.7% vs 17.6%(P=0.0165)。

要点

  • 预设疗效集为基线推算PaO2/FiO2≤200的重症COVID-19肺炎患者261例,Auxora组130例、安慰剂组131例。
  • Auxora组恢复时间7天 vs 安慰剂组10天(P=0.0979),未达统计学显著。
  • 第60天全因死亡率Auxora组13.8% vs 安慰剂组20.6%(P=0.1449),未达统计学显著。
  • 第30天全因死亡率Auxora组7.7% vs 安慰剂组17.6%(P=0.0165)。
  • 严重不良事件Auxora组34例(24.1%) vs 安慰剂组49例(35.0%)(P=0.0616),最常见为呼吸衰竭、急性呼吸窘迫综合征和肺炎。

适用人群与场景

  • 成人重症COVID-19肺炎患者,需≥1项与COVID-19感染一致的症状,经聚合酶链反应或其他检测实验室确诊COVID-19,胸部影像学证实肺炎。
  • 入组时需接受高流量或低流量鼻导管氧疗,基线推算PaO2/FiO2>75且≤300;PaO2/FiO2由脉搏血氧饱和度测得的SpO2/FiO2通过非线性方程推算。
  • 入组时不能接受无创或有创机械通气。

诊断标准与关键阈值

  • 基线推算PaO2/FiO2>75且≤300为入组条件。
  • 预设疗效集定义为基线推算PaO2/FiO2≤200的患者。

处置流程与药物剂量

  • 在皮质类固醇和标准治疗基础上加用Auxora(CRAC通道抑制剂)。

研究设计与关键结果

  • CARDEA为2期随机双盲安慰剂对照试验,评估Auxora加入皮质类固醇和标准治疗;因COVID-19住院率下降及监管指南禁止的标准治疗药物使用,试验提前终止。
  • 预设疗效集为基线推算PaO2/FiO2≤200的261例患者,Auxora组130例、安慰剂组131例。
  • 恢复时间Auxora组7天 vs 安慰剂组10天(P=0.0979)。
  • 第60天全因死亡率Auxora组13.8% vs 安慰剂组20.6%(P=0.1449);第30天全因死亡率Auxora组7.7% vs 安慰剂组17.6%(P=0.0165)。
  • 在所有随机患者、基线使用高流量鼻导管患者或基线推算PaO2/FiO2≤100患者中观察到相似趋势。
  • 严重不良事件Auxora组34例(24.1%) vs 安慰剂组49例(35.0%)(P=0.0616);最常见严重不良事件为呼吸衰竭、急性呼吸窘迫综合征和肺炎。

证据类型、等级与局限

  • 证据类型:2期随机双盲安慰剂对照试验(CARDEA,NCT04345614)。
  • 局限:因COVID-19住院率下降及监管指南禁止的标准治疗药物使用,试验提前终止;作者结论指出需要进一步研究Auxora在重症COVID-19肺炎患者中的应用。

对床旁实践的改变

  • 作者认为Auxora安全且耐受性良好,在重症COVID-19肺炎患者的恢复时间和至第60天全因死亡率方面显示出强烈信号;作者认为需要进一步研究Auxora在重症COVID-19肺炎患者中的应用。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Calcium release-activated calcium (CRAC) channel inhibitors block proinflammatory cytokine release, preserve endothelial integrity and may effectively treat patients with severe COVID-19 pneumonia.

METHODS: CARDEA was a phase 2, randomized, double-blind, placebo-controlled trial evaluating the addition of Auxora, a CRAC channel inhibitor, to corticosteroids and standard of care in adults with severe COVID-19 pneumonia. Eligible patients were adults with ≥ 1 symptom consistent with COVID-19 infection, a diagnosis of COVID-19 confirmed by laboratory testing using polymerase chain reaction or other assay, and pneumonia documented by chest imaging. Patients were also required to be receiving oxygen therapy using either a high flow or low flow nasal cannula at the time of enrolment and have at the time of enrollment a baseline imputed PaO2/FiO2 ratio > 75 and ≤ 300. The PaO2/FiO2 was imputed from a SpO2/FiO2 determine by pulse oximetry using a non-linear equation. Patients could not be receiving either non-invasive or invasive mechanical ventilation at the time of enrolment. The primary endpoint was time to recovery through Day 60, with secondary endpoints of all-cause mortality at Day 60 and Day 30. Due to declining rates of COVID-19 hospitalizations and utilization of standard of care medications prohibited by regulatory guidance, the trial was stopped early.

RESULTS: The pre-specified efficacy set consisted of the 261 patients with a baseline imputed PaO2/FiO2≤ 200 with 130 and 131 in the Auxora and placebo groups, respectively. Time to recovery was 7 vs. 10 days (P = 0.0979) for patients who received Auxora vs. placebo, respectively. The all-cause mortality rate at Day 60 was 13.8% with Auxora vs. 20.6% with placebo (P = 0.1449); Day 30 all-cause mortality was 7.7% and 17.6%, respectively (P = 0.0165). Similar trends were noted in all randomized patients, patients on high flow nasal cannula at baseline or those with a baseline imputed PaO2/FiO2 ≤ 100. Serious adverse events (SAEs) were less frequent in patients treated with Auxora vs. placebo and occurred in 34 patients (24.1%) receiving Auxora and 49 (35.0%) receiving placebo (P = 0.0616). The most common SAEs were respiratory failure, acute respiratory distress syndrome, and pneumonia.

CONCLUSIONS: Auxora was safe and well tolerated with strong signals in both time to recovery and all-cause mortality through Day 60 in patients with severe COVID-19 pneumonia. Further studies of Auxora in patients with severe COVID-19 pneumonia are warranted. Trial registration NCT04345614.

来源:Crit Care,查看原文。版权归原作者所有。

参考来源

  1. Bruen C, Al-Saadi M, Michelson EA, et al. Auxora vs. placebo for the treatment of patients with severe COVID-19 pneumonia: a randomized-controlled clinical trial. Crit Care. 2022. PMID: 35395943. doi:10.1186/s13054-022-03964-8

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。